Ustekinumab May Trigger Acute CV Events Early in Treatment Ustekinumab May Trigger Acute CV Events Early in Treatment
Initiating treatment with ustekinumab, an IL-12/23-targeting monoclonal antibody, may trigger early severe cardiovascular events in susceptible patients.Medscape Medical News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - September 18, 2020 Category: Dermatology Tags: Dermatology News Source Type: news
FDA Approves Stelara (ustekinumab) for Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
HORSHAM, Pa., July 30, 2020 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson& Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for Stelara (ustekinumab) as a treatment... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 30, 2020 Category: Drugs & Pharmacology Source Type: news
Johnson & Johnson Reports 2020 Second-Quarter Results
New Brunswick, N.J. (July 16, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for second-quarter 2020. “Our second quarter results reflect the impact of COVID-19 and the enduring strength of our Pharmaceutical business, where we saw continued growth even in this environment,” said Alex Gorsky, Chairman and Chief Executive Officer. “Thanks to the tireless work of our colleagues around the world and our broad range of capabilities, we continue to successfully navigate the external landscape, and we remain focused on advancing the development of a vaccine to help address this pandemic and save lives....
Source: Johnson and Johnson - July 16, 2020 Category: Pharmaceuticals Source Type: news
Janssen Announces Discontinuation of Phase 3 LOTUS Study Evaluating Ustekinumab in Systemic Lupus Erythematosus
SPRING HOUSE, PENNSYLVANIA, June 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today its decision to discontinue the Phase 3 LOTUS study of STELARA® (ustekinumab) in Systemic Lupus Erythematosus (SLE) due to lack of efficacy in SLE.The decision is based on data from a pre-planned interim efficacy analysis. Interim safety findings were consistent with the known safety profile of STELARA, and no new safety signals were identified. Investigators, study participants and health authorities have been informed of the decision. The company intends to thoroughly analyze the totality of the st...
Source: Johnson and Johnson - June 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Announces Discontinuation of Phase 3 LOTUS Study Evaluating Ustekinumab in Systemic Lupus Erythematosus
SPRING HOUSE, Pa., June 26, 2020 -- (Healthcare Sales & Marketing Network) -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today its decision to discontinue the Phase 3 LOTUS study of STELARA® (ustekinumab) in Systemic Lupus Ery... Biopharmaceuticals Janssen Pharmaceutical, Johnson & Johnson, STELARA, ustekinumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 26, 2020 Category: Pharmaceuticals Source Type: news
Johnson & Johnson Reports 2020 First-Quarter Results:
New Brunswick, N.J. (April 14, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2020. The Company also announced earlier today that its Board of Directors declared a 6.3% increase in the quarterly dividend rate, from $0.95 per share to $1.01 per share. At the new rate, the indicated dividend on an annual basis is $4.04 per share compared to the previous rate of $3.80 per share. “With Johnson & Johnson’s century-plus history of leading in times of great challenge, we are mobilizing our resources across the Company in the fight against the COVID-19 pandemic,” said Alex Gorsky, C...
Source: Johnson and Johnson - April 14, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news
Ustekinumab reduces costs and utilisation in US patients with Crohn's disease
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - March 31, 2020 Category: Drugs & Pharmacology Source Type: news
FDA OKs Ustekinumab (Stelara) for Moderate to Severe UC FDA OKs Ustekinumab (Stelara) for Moderate to Severe UC
Ustekinumab was more effective than placebo for inducing and maintaining remission and promoting mucosal healing in a study of adults with moderately to severely active ulcerative colitis.FDA Approvals (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - October 21, 2019 Category: Internal Medicine Tags: Gastroenterology News Alert Source Type: news
Janssen Announces FDA Approval of Stelara (ustekinumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis
HORSHAM, PENNSYLVANIA, October 21, 2019– The Janssen Pharmaceutical Companies of Johnson& Johnson announced today the U.S. Food and Drug Administration’s (FDA) approval of Stelara (ustekinumab) for the treatment of adult patients... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 21, 2019 Category: Drugs & Pharmacology Source Type: news
Janssen Announces U.S. FDA Approval of STELARA ® (ustekinumab) for the Treatment of Adults with Moderately to Severely Active Ulcerative
In the Phase 3 pivotal trial, more than 40 percent of patients receiving STELARA subcutaneous (SC) injections every 8 weeks were in clinical remission at one year and not taking corticosteroidsSTELARA is the first and only approved treatment for ulcerative colitis to demonstrate improvement of the colon as measured by a novel histologic-endoscopic mucosal improvement endpoint (Source: Johnson and Johnson)
Source: Johnson and Johnson - October 21, 2019 Category: Pharmaceuticals Source Type: news
Vedolizumab Beats Adalimumab for Ulcerative Colitis Remissions
WEDNESDAY, Sept. 25, 2019 -- In moderate-to-severe ulcerative colitis, vedolizumab is superior to adalimumab for achieving clinical remission and endoscopic improvement, but not corticosteroid-free clinical remission, and ustekinumab is superior to... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 25, 2019 Category: Pharmaceuticals Source Type: news
Sarcoid-Like Ustekinumab Induced Granulomatous Reaction Sarcoid-Like Ustekinumab Induced Granulomatous Reaction
This patient presented with a rare disseminated sarcoid-like reaction while undergoing treatment with the monoclonal antibody ustekinumab for refractory psoriasis.Journal of Medical Case Reports (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 28, 2019 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news
ustekinumab (Stelara)
Title: ustekinumab (Stelara)Category: MedicationsCreated: 1/5/2010 12:00:00 AMLast Editorial Review: 8/5/2019 12:00:00 AM (Source: MedicineNet Skin General)
Source: MedicineNet Skin General - August 5, 2019 Category: Dermatology Source Type: news
Risankizumab vs. Ustekinumab for Plaque Psoriasis Risankizumab vs. Ustekinumab for Plaque Psoriasis
A recent head-to-head study compared risankizumab with ustekinumab for treatment of moderate-to-severe chronic plaque psoriasis. This critical assessment examines the validity of the results.The British Journal of Dermatology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 1, 2019 Category: Consumer Health News Tags: Dermatology Journal Article Source Type: news
Infection Risk Lower With Certain Psoriasis Treatments
MONDAY, May 13, 2019 -- For patients with psoriasis treated with systemic medications, the risk for serious infection is reduced for new users of apremilast, etanercept, and ustekinumab versus methotrexate, according to a study published online May... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 13, 2019 Category: Pharmaceuticals Source Type: news
